Related references
Note: Only part of the references are listed.Minimal change disease associated with anti-PD1 immunotherapy: a case report
Bixia Gao et al.
BMC NEPHROLOGY (2018)
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2017)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases
Abhijat Kitchlu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Acute interstitial nephritis related to immune checkpoint inhibitors
Julie Belliere et al.
BRITISH JOURNAL OF CANCER (2016)
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas K. Eigentler et al.
CANCER TREATMENT REVIEWS (2016)
Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma
Michael C. Kirchberger et al.
EUROPEAN JOURNAL OF CANCER (2016)
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Saskia Herz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar et al.
KIDNEY INTERNATIONAL (2016)
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
Naoka Murakami et al.
CLINICAL KIDNEY JOURNAL (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: Report of 21 cases and review of the literature
V. Audard et al.
KIDNEY INTERNATIONAL (2006)
Share Paper
